Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611731 | 0.89 | CYP2A6 (0.46) | ACHELMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3540663 | 0.89 | IDO1 (0.41) | LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1515692 | 0.81 | ALDH1A1 (0.42) | NFE2L2LMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL1515700 | 0.81 | LMNA (0.46) | ACHENFE2L2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20521097 | 0.81 | ALDH1A1 (0.42) | NFE2L2LMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL26999415 | 0.79 | ACHE (0.54) | ACHELMNAALDH1A1TDP1CYP2A6 | |
| SCHEMBL26999435 | 0.79 | ALDH1A1 (0.54) | ACHELMNAALDH1A1TDP1CYP2A6 | |
| SCHEMBL26999433 | 0.79 | CES2 (0.45) | TDP1CYP2A6DRD2DRD4DRD3 | |
| SCHEMBL26999419 | 0.79 | ESR1 (0.40) | LMNAALDH1A1TDP1GAADRD3 | |
| SCHEMBL20703707 | 0.79 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873315-B2 | Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2024-01-16 | — | — | US | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873315-B2 | Chiral n-heterocyclic phosphorodiamidic acids (NHPAS) and derivatives as novel Brønsted acid catalysts | ELANE, PNKP, SERPINB1 | ACHE 143/4885NFE2L2 3727/4885LMNA 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.